Last reviewed · How we verify
NCT07341932
Helium-free Magnetocardiography Guided Therapy for Stable Coronary Artery Disease - A Randomized Controlled Trial
NA trial testing MCG Group in Stable Coronary Artery Disease CAD in 1,312 participants. Currently enrolling.
1 June 2027
Quick facts
| Lead sponsor | Beijing Anzhen Hospital |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 1,312 |
| Start date | 17 March 2026 |
| Primary completion | 1 June 2027 |
| Estimated completion | 1 December 2027 |
| Sites | 5 locations across China |
Drugs / interventions tested
- MCG Group
- Conventional Management Group
Conditions studied
- Stable Coronary Artery Disease CAD — all drugs for Stable Coronary Artery Disease CAD →
Sponsor
Beijing Anzhen Hospital
Who can join
Adults 18 to 80, any sex, with Stable Coronary Artery Disease CAD. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This rigorously designed randomized controlled trial aims to investigate whether Magnetocardiography (MCG) can optimize the clinical pathway, improve quality of life, and reduce healthcare costs in patients with stable coronary artery disease (SCAD) within real-world clinical settings, thereby generating evidence for the future application of MCG in clinical decision-making pathways. Stable CAD patients with at least one major coronary vessel showing 50%-90% stenosis on coronary CTA will be enrolled based on predefined criteria. Stratified by study center and using a central web-based randomization system, participants will be allocated in a 1:1 ratio to either the \*\*MCG-guided group\*\* (where treatment recommendations for invasive coronary angiography \[ICA\] or optimal medical therapy are based on MCG results) or the \*\*conventional management group\*\* (where treatment strategy is based on stenosis severity, pre-test probability, and functional test results). The study will proceed with the following evaluations: 1. Compare the proportion of patients with non-obstructive coronary artery disease on planned ICA performed within 90 days between the two groups, testing the hypothesis that this proportion is lower in the MCG-guided group. 2. Conduct telephone follow-ups at 90 days, 6 months, and 12 months post-enrollment to compare between-group differences in the rate of Major Adverse Cardiovascular Events (MACE), Seattle Angina Questionnaire (SAQ) scores, and total healthcare expenditures during the follow-up period.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07341932
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Stable Coronary Artery Disease CAD
Currently open trials in the same condition.
- NCT07195149 — Comparing High and lOw-dose asPirin With Dual anTIplatelet Therapy for Three Months Using prasUgrel and aSpirin Followin · Phase 3 · recruiting
- NCT06717074 — A Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of RBD4059 in Participants With Stable Coronary Artery · Phase 2 · active not recruiting
Other Beijing Anzhen Hospital trials
Trials by the same sponsor.
- NCT07521488 — LLM-Based Intelligent Health Management Assistant in Life-Cycle Health Management of Cardiac Surgery Patients · NA · not yet recruiting
- NCT07470814 — Multidisciplinary Collaborative Care System for Acute Myocardial Infarction Complicated With Cardiogenic Shock · not yet recruiting
- NCT07444372 — Start CPAP Therapy in Obstructive Sleep Apnea Patients After Atrial Fibrillation Ablation · NA · not yet recruiting
- NCT07485101 — Glycemic Targets During CPB in Elderly Diabetes · NA · not yet recruiting
- NCT07256197 — PCSK9 Inhibitors in the Treatment of Calcific Aortic Stenosis · Phase 3 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07341932 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Beijing Anzhen Hospital
- Last refreshed: 2 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07341932.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing